文献速递青光眼

快速进展性青光眼:治疗升级的临床、结构与社会经济驱动因素

Rapidly Progressing Glaucoma: Clinical, Structural, and Socioeconomic Drivers of Treatment Escalation.
PubMed 文献 · Ophthalmology · 2025-10-10

该回顾性队列研究纳入1812名成人共2782只眼,评估与快速视野进展青光眼患者治疗选择相关的临床和社会人口学因素。快速进展者接受激进手术的比值显著更高(OR 6.96,95%CI 2.61-18.55,P<0.001),但仅23%在最初7年内接受激进手术。社会脆弱性指数更高(更差)与快速进展者接受微创手术的可能性降低相关(OR 0.06,95%CI 0.00-0.78,P=0.032)。

要点

  • 快速进展者接受激进手术的OR为6.96(95%CI 2.61-18.55,P<0.001)。
  • 仅23%的快速进展者在最初7年内接受激进手术。
  • 快速进展者中更高(更差)SVI与接受微创手术可能性降低相关(OR 0.06,95%CI 0.00-0.78,P=0.032)。

核心结论

  • 快速进展是激进手术的强预测因素,但不到四分之一的患者在最初7年内接受了激进降眼压干预。
  • 在快速进展者中,功能下降速率未在治疗选择中发挥作用。
  • 社会经济脆弱性较高地区的快速进展患者接受微创手术的可能性也较低。
  • 更好地整合功能下降速率并解决社会经济障碍可能有助于优化快速进展性青光眼患者的诊疗。

研究设计与样本

  • 回顾性队列研究,纳入1812名成人共2782只眼,要求5年内至少5次24-2视野检查且基线至少1次OCT扫描。
  • 快速进展者定义为平均偏差(MD)斜率差于-1分贝(dB)/年。
  • 根据最初7年内接受的最强化治疗分为药物治疗、微创操作(如微创青光眼手术或激光)或激进操作(如滤过手术或外部睫状体破坏)。
  • 采用多项式回归识别与治疗强度相关的社会人口学、临床和社会经济因素。

主要发现

  • 快速进展者接受激进操作的比值显著更高(OR 6.96,95%CI 2.61-18.55,P<0.001),但仅23%的快速进展者在最初7年内接受了激进操作。
  • 在仅接受药物治疗的快速进展者样本中,85%因临床医生决策而非患者偏好而接受保守治疗。
  • 更差的MD、更小的盘沿面积和更高的初始眼压与更激进的干预相关。
  • 在快速进展者中,功能下降(MD斜率)与治疗选择无关。
  • 在快速进展者中,更高(更差)的SVI与接受微创操作的可能性降低相关(OR 0.06,95%CI 0.00-0.78,P=0.032)。

关键数值与推荐

  • 快速进展者接受激进操作的OR为6.96(95%CI 2.61-18.55,P<0.001),但仅23%在最初7年内接受激进操作。
  • 仅接受药物治疗的快速进展者中,85%因临床医生决策而非患者偏好接受保守治疗。
  • 快速进展者中更高(更差)SVI与接受微创操作可能性降低相关(OR 0.06,95%CI 0.00-0.78,P=0.032)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate clinical and sociodemographic factors associated with selecting treatments in glaucoma patients with rapid visual field (VF) progression. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 2782 eyes from 1812 adults with 5 or more 24-2 VFs over 5 years and at least 1 OCT scan at baseline. METHODS: Rapid progressors were defined by mean deviation (MD) slopes worse than -1 decibels (dB)/year. Demographic (age, gender, race), clinical (intraocular pressure [IOP], VF metrics, OCT measures), and socioeconomic (Social Vulnerability Index [SVI]) variables were collected. Patients were categorized based on the most intensive treatment received in the first 7 years: medical management, minimally invasive procedures (e.g., minimally invasive glaucoma surgery or laser), or aggressive procedures (e.g., filtering surgery or external ciliodestruction). Multinomial regression was performed to identify demographic, clinical, and socioeconomic factors associated with treatment intensity. MAIN OUTCOME MEASURES: Odds of treatment selection based on rapid VF progression. RESULTS: Rapid progressors had significantly higher odds of receiving aggressive procedures (odds ratio [OR], 6.96, 95% confidence interval [CI], 2.61-18.55, P < 0.001), yet only 23% of rapid progressors underwent aggressive procedures in the first 7 years. In a sample of rapid progressors who were managed with medical treatment alone, we found that 85% were conservatively managed due to clinician decision-making rather than patient preference. Worse MD, smaller rim area, and higher initial IOP were associated with more aggressive intervention. Functional decline (MD slope) was not associated with treatment selection in rapid progressors. We also found that higher (worse) SVI was associated with a reduced likelihood of receiving minimally invasive procedures among rapid progressors (OR, 0.06, 95% CI, 0.00-0.78, P = 0.032). CONCLUSIONS: Although rapid progression was a strong predictor of aggressive procedures, fewer than 1 in 4 patients underwent aggressive IOP-lowering interventions in the first 7 years. Rate of functional decline did not play a role in treatment selection within rapid progressors. Rapidly progressing patients in areas of higher socioeconomic vulnerability were also less likely to receive less-invasive procedures. Better integrating rates of functional decline and addressing socioeconomic barriers may help optimize care for patients with rapidly progressing glaucoma. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Lee LH, Xie Y, Pan A, et al. Rapidly Progressing Glaucoma: Clinical, Structural, and Socioeconomic Drivers of Treatment Escalation. Ophthalmology. 2025. PMID: 41077358. doi:10.1016/j.ophtha.2025.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。